Dissecting therapeutic resistance to ERK inhibition

Molecular Cancer Therapeutics

Volumn 15, Issue 4, 2016, Pages 548-559

  Jha, Sharda ^a   Morris, Erick J ^a,b   Hruza, Alan ^a   Mansueto, My Sam ^a   Schroeder, Gottfried K ^a   Arbanas, Jaren ^a   McMasters, Daniel ^a   Restaino, Clifford R ^a   Dayananth, Priya ^a   Black, Stuart ^a   Elsen, Nathaniel L ^a   Mannarino, Anthony ^a   Cooper, Alan ^a,c   Fawell, Stephen ^a,d   Zawel, Leigh ^a,e   Jayaraman, Lata ^a,f   Samatar, Ahmed A ^a,g  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Translational and Experimental Medicine   (United States)

^c Cooper Medchem Consulting LLC ^*  (United States)

^d ASTRAZENECA   (United Kingdom)

^e PFIZER INC   (United States)

^f Cerulean Pharma Inc   (United States)

^g TheraMet Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTIC ACID; B RAF KINASE; GLYCINE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; RAF PROTEIN; RAS PROTEIN; SCH 772984; TRAMETINIB; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING KINETICS; CELL PROLIFERATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REACTIVATION; GENE FREQUENCY; HYDROGEN BOND; IC50; LONG TERM EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CONFORMATION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; TUMOR RESISTANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; CONFORMATION; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL; NEOPLASMS; RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASMS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RATS;

EID: 84964320723     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0172     Document Type: Article

References (32)

1. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. JNatl Cancer Inst 2001;93:1062-74.
2. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer 2011;2:344-58.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
4. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44:1006-14.
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
6. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
7. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.
8. Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov 2011;10:811-2.
9. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65.
10. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010;3: ra84.
11. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012;2:227-35.
12. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 2013;3:158-67.
13. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature 2011;480:387-90.
14. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014;4:80-93.
15. Shi H, Kong X, Ribas A, Lo RS. Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 2011;71:5067-74.
16. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E) B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012;3:724.
17. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2013;4:94-109.
18. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition inmelanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085-96.
19. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009;106:20411-6.
20. Wang H, Daouti S, Li WH, Wen Y, Rizzo C, Higgins B, et al. Identification of the MEK1 (F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the BRafV600E mutation. Cancer Res 2011;71:5535-45.
21. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 2012;11:909-20.
22. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 2014;20:1965-77.
23. Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013;3:742-50.
24. Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, et al. Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer 2014;13:194.
25. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 2010;66:486-501.
26. Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res 2014;20:2249-56.
27. Rudolph J, Xiao Y, Pardi A, Ahn NG. Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitors. Biochemistry 2015;54:22-31.
28. Chaikuad A, Tacconi EM, Zimmer J, Liang Y, Gray NS, Tarsounas M, et al. A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nat Chem Biol 2014;10:853-60.
29. Zhang F, Strand A, Robbins D, Cobb MH, Goldsmith EJ. Atomic structure of the MAP kinase ERK2 at 2.3 A resolution. Nature 1994;367:704-11.
30. Zhang J, Shapiro P, Pozharski E. Structure of extracellular signal-regulated kinase 2 in complex with ATP and ADP. Acta Crystallogr Sect F Struct Biol Cryst Commun 2012;68:1434-9.
31. Wilsbacher JL, Goldsmith EJ, Cobb MH. Phosphorylation of MAP kinases by MAP/ERK involves multiple regions of MAP kinases. J Biol Chem 1999;274:16988-94.
32. Emrick MA, Lee T, Starkey PJ, Mumby MC, Resing KA, Ahn NG. The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity. Proc Natl Acad Sci U S A 2006;103:18101-6.